New Evidence on the Impact of Cervical Cancer Screening and Treatment Using HPV DNA Tests, Visual Inspection or Cytology
Routine cytological screening of women has resulted in a dramatic decline in cervical cancer deaths over the past four decades in wealthier countries. A key reason for continuing high mortality in the developing world is the shortage of efficient, high-quality precancer screening and treatment programs in those regions.
Most developing countries lack the infrastructure and trained personnel needed to replicate the cytology-based, multi-visit approach used in wealthier countries to detect precancer (Pap smears followed by colposcopy and biopsy).
In an effort to investigate sustainable alternatives to cytological screening, the ACCP —EngenderHealth, International Agency for Research on Cancer (IARC), Jhpiego, Pan American Health Organization (PAHO), and PATH — implemented a coordinated research agenda aimed at assessing a variety of approaches to cervical cancer screening and treatment (especially approaches that may be better suited to low-resource settings).
The ACCP also focused on improving service-delivery systems — ensuring that community perspectives and needs are incorporated into program design — and raising awareness of cervical cancer and effective prevention strategies.
Add A New CommentWe value and respect the experiences of all of our HerWriters, but everyone is different. Many of our writers are speaking from personal experience, and what's worked for them may not work for you. Their articles are not a substitute for medical advice although we hope you can gain knowledge from their insight.
Add A New CommentComments
There are no comments yet. Be the first to get the conversation started.